Answers are grounded in this paper and cite their sources.
TO THEEDITOR: A few months ago, we reported in a large pooled analysis the clinical validity of circulating tumor cells (CTC) as a dynamic prognostic biomarker in 1,944 patients with metastatic breast cancer; moreover, this study demonstrated the superiority of CTC count over the serum markers carcinoembryonic antigen and CA15-3. 1 In light these results, recently published survival outcomes in the SWOG S0500 randomized trial may appear disappointing. 2 These negative results were however foreseen—not because of the CTC detection technique itself, but for reasons related to the way the test was developed. The issue of chemoresistance to first line being often associated with a broad resistance to subsequent lines of therapy is discussed in the article and is probably the best explanation for the trial’s results. Janni et al 3 also noticed that early switch to second-line chemotherapy has never demonstrated a clinical utility in metastatic breast cancer, whatever the tool used (positron emission tomography scanner, serum markers . . .). We propose some other issues should be also taken into account to fully understand the published results: First, the CTC response test is basically meant to detect early resistance to treatment. Whatever its intrinsic characteristics (sensitivity, specificity), the CTC test would have probably exhibited better performances (number of false positive and false negative) in a population with a high prevalence of chemoresistance (ie, after the first line[s] of therapy). Second, in an ideal scenario, the CTC test would have 100% sensitivity and specificity to detect early tumor progression: patients with early chemoresistance would have been switched off ineffective first-line chemotherapy after 1 month of treatment in the CTC arm and after 3 months of treatment in the standard arm (radiological evaluation). In that most favorable scenario, second-line therapy would have been initiated 2 months earlier in the CTC arm than in the standard arm. Notwithstanding the real performances of the CTC test, this 2-month difference at the initial beginning of the metastatic disease was unlikely to translate into a significant increase of overall survival (main study end point) for the 60 patients randomly assigned in the CTC arm. Third, threshold defined for clinical validity may differ from those relevant for clinical utility. The 5 CTC/7.5 mL threshold was initially optimized as a baseline prognostic biomarker. 4 This threshold allowed distinguishing two populations of patients with metastatic breast cancer with good versus bad survival with a high hazard ratio and a significant P value. However, we do not know whether 5 CTC/7.5 mL during treatment is the best threshold as an early resistance screening test. In future trials, we would recommend to check that thresholds used for clinical utility translate into high sensitivity
No takes yet. Share an insight, caveat, or question.
Bidard et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: